Leveraging Fungal Calcineurin-Inhibitor Structures, Biophysics and Dynamics to Design Selective and Non-Immunosuppressive FK506 Analogs

dc.contributor.author

Gobeil, Sophie M-C

dc.contributor.author

Bobay, Benjamin

dc.contributor.author

Juvvadi, Praveen

dc.contributor.author

Cole, Christopher

dc.contributor.author

Heitman, Joseph

dc.contributor.author

Steinbach, William

dc.contributor.author

Venters, Ronald

dc.contributor.author

Spicer, Leonard

dc.date.accessioned

2023-09-01T14:23:39Z

dc.date.available

2023-09-01T14:23:39Z

dc.date.issued

2020

dc.date.updated

2023-09-01T14:23:38Z

dc.description.abstract

Calcineurin is a critical enzyme in fungal pathogenesis and antifungal drug tolerance and, therefore, an attractive antifungal target. Current clinically-accessible calcineurin inhibitors, such as FK506, are immunosuppressive to humans, so exploiting calcineurin inhibition as an antifungal strategy necessitates fungal-specificity in order to avoid inhibiting the human pathway. Harnessing fungal calcineurin-inhibitor crystal structures, we recently developed a less immunosuppressive FK506 analog, APX879, with broad-spectrum antifungal activity and demonstrable efficacy in a murine model of invasive fungal infection. Our overarching goal is to better understand, at a molecular level, the interaction determinants of the human and fungal FK506-binding proteins (FKBP12) required for calcineurin inhibition in order to guide the design of fungal-selective, non-immunosuppressive FK506 analogs. To this end, we characterized high-resolution structures of the M. circinelloides FKBP12 bound to FK506, and of the A. fumigatus, M. circinelloides and human FKBP12 proteins bound to the FK506 analog, APX879, which exhibits enhanced selectivity for fungal pathogens. Combining structural, genetic and biophysical methodologies with molecular dynamics simulations, we identify critical variations in these structurally similar FKBP12-ligand complexes that will guide the rational design of inhibitors with enhanced fungal-selectivity.

Significance statement

Invasive fungal infections are a leading cause of death in the immunocompromised patient population. The rise in drug resistance to current antifungals highlights the urgent need to develop more efficacious and highly selective agents. Numerous investigations of major fungal pathogens have confirmed the critical role of the calcineurin pathway for fungal virulence, making it an attractive target for antifungal development. Although FK506 inhibits calcineurin, it is immunosuppressive in humans and cannot be used as an antifungal. By combining structural, genetic, biophysical, and in silico methodologies, we pinpoint regions of FK506 and a less immunosuppressive analog, APX879, that could be altered to enhance fungal selectivity. This work represents a significant advancement toward realizing calcineurin as a viable target for antifungal drug discovery.

dc.identifier.issn

2150-7511

dc.identifier.uri

https://hdl.handle.net/10161/28915

dc.relation.ispartof

MBIO

dc.relation.isversionof

10.1101/2020.04.14.039800

dc.subject

FK506

dc.subject

FKBP12

dc.subject

APX879

dc.subject

antifungals

dc.subject

M. circinelloides

dc.subject

A. fumigatus

dc.subject

NMR

dc.subject

X-ray crystal structures

dc.subject

isothermal titration calorimetry (ITC)

dc.subject

molecular dynamic (MD)

dc.title

Leveraging Fungal Calcineurin-Inhibitor Structures, Biophysics and Dynamics to Design Selective and Non-Immunosuppressive FK506 Analogs

dc.type

Journal article

duke.contributor.orcid

Gobeil, Sophie M-C|0000-0002-0057-2477

duke.contributor.orcid

Bobay, Benjamin|0000-0003-4775-3686

duke.contributor.orcid

Heitman, Joseph|0000-0001-6369-5995

duke.contributor.orcid

Venters, Ronald|0000-0001-6457-823X

duke.contributor.orcid

Spicer, Leonard|0000-0001-5655-0093|0000-0003-2911-6130

pubs.issue

6

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Faculty

pubs.organisational-group

Staff

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biochemistry

pubs.organisational-group

Cell Biology

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Medicine

pubs.organisational-group

Radiology

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Human Vaccine Institute

pubs.publication-status

Published

pubs.volume

12

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
mbio.03000-21.pdf
Size:
4.16 MB
Format:
Adobe Portable Document Format
Description:
Published version